Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in alzheimer's disease

  • Rodriguez Rodriguez, Cristina|||0000-0002-3313-4422
  • Sánchez de Groot, Natalia|||0000-0002-0492-5532
  • Rimola, Albert|||0000-0002-9637-4554
  • Álvarez-Fernández, Alejandra|||0000-0002-1906-0180
  • Lloveras Monserrat, Vega|||0000-0002-9653-3340
  • Vidal-Gancedo, José|||0000-0002-1853-9675
  • Ventura, Salvador|||0000-0002-9652-6351
  • Vendrell Roca, Josep|||0000-0002-9378-4742
  • Sodupe, Mariona|||0000-0003-0276-0524
  • González Duarte, Pilar
Metal chelation is considered a rational therapeutic approach for interdicting Alzheimer's amyloid pathogenesis. At present, enhancing the targeting and efficacy of metal-ion chelating agents through ligand design is a main strategy in the development of the next generation of metal chelators. Inspired by the traditional dye Thioflavin-T, we have designed new multifunctional molecules that contain both amyloid binding and metal chelating properties. In silico techniques have enabled us to identify commercial compounds that enclose the designed molecular framework (M1), include potential antioxidant properties, facilitate the formation of iodine-labeled derivatives, and can be permeable through the blood-brain barrier. lodination reactions of the selected compounds, 2-(2-hydroxyphenyl)benzoxazole (HBX), 2-(2-hydroxyphe- nyl)benzothiazole (HBT), and 2-(2-aminophenyl)-1 H-benzimidazole (BM), have led to the corresponding iodinated derivatives HBXI, HBTI, and BMI, which have been characterized by X-ray diffraction. The chelating properties of the latter compounds toward Cu(ll) and Zn(ll) have been examined in the solid phase and in solution. The acidity constants of HBXI, HBTI, and BMI and the formation constants of the corresponding ML and ML2 complexes [M = Cu(ll), Zn(ll)] have been determined by UV-vis pH titrations. The calculated values for the overall formation constants for the ML 2 complexes indicate the suitability of the HBXI, HBTI, and BMI ligands for sequestering Cu(ll) and Zn(ll) metal ions present in freshly prepared solutions of β-amyloid (Aβ) peptide. This was confirmed by Aβ aggregation studies showing that these compounds are able to arrest the metal-promoted increase in amyloid fibril buildup. The fluorescence features of HBX, HBT, BM, and the corresponding iodinated derivatives, together with fluorescence microscopy studies on two types of pregrown fibrils, have shown that HBX and HBT compounds could behave as potential markers for the presence of amyloid fibrils, whereas HBXI and HBTI may be especially suitable for radioisotopic detection of Aβ deposits. Taken together, the results reported in this work show the potential of new multifunctional thioflavin-based chelating agents as Alzheimer's disease therapeutics.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

AGGRESCAN, a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides

  • Conchillo-Solé, Oscar|||0000-0003-4266-246X
  • Sánchez de Groot, Natalia|||0000-0002-0492-5532
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Vendrell i Roca, Josep|||0000-0002-9378-4742
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Ventura, Salvador|||0000-0002-9652-6351
Background: Protein aggregation correlates with the development of several debilitating human disorders of growing incidence, such as Alzheimer's and Parkinson's diseases. On the biotechnological side, protein production is often hampered by the accumulation of recombinant proteins into aggregates. Thus, the development of methods to anticipate the aggregation properties of polypeptides is receiving increasing attention. AGGRESCAN is a web-based software for the prediction of aggregation-prone segments in protein sequences, the analysis of the effect of mutations on protein aggregation propensities and the comparison of the aggregation properties of different proteins or protein sets. Results: AGGRESCAN is based on an aggregation-propensity scale for natural amino acids derived from in vivo experiments and on the assumption that short and specific sequence stretches modulate protein aggregation. The algorithm is shown to identify a series of protein fragments involved in the aggregation of disease-related proteins and to predict the effect of genetic mutations on their deposition propensities. It also provides new insights into the differential aggregation properties displayed by globular proteins, natively unfolded polypeptides, amyloidogenic proteins and proteins found in bacterial inclusion bodies. Conclusion: By identifying aggregation-prone segments in proteins, AGGRESCAN http://bioinf.uab.es/aggrescan/ webcite shall facilitate (i) the identification of possible therapeutic targets for anti-depositional strategies in conformational diseases and (ii) the anticipation of aggregation phenomena during storage or recombinant production of bioactive polypeptides or polypeptide sets.